
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd has demonstrated a positive outlook primarily due to the successful Phase 3 results of its drug candidate brepocitinib, which shows significant efficacy across skin and muscle manifestations in dermatomyositis, enhancing investor confidence and sentiment. The company's pipeline includes promising candidates like IMVT-1402 for Graves' disease, which is strategically positioned against growing competition, and batoclimab, notable for being the first clinical candidate exhibiting disease-modifying potential in this patient population. The recent increase in revenue estimates for IMVT-1402 further underscores Roivant's strengthening financial projections, emphasizing the potential for future growth within a competitive biopharmaceutical landscape.
Bears say
The financial outlook for Roivant Sciences Ltd is negatively impacted by the failure of several key drug candidates in clinical trials, including brepocitinib and other assets from the IMVT portfolio, raising concerns regarding the company's pipeline viability. Additionally, there are warnings about potential off-target effects from certain mechanisms, which could complicate future developments and regulatory approvals. Finally, the ongoing challenges in achieving clinically significant results in treating conditions such as dermatomyositis and non-infectious uveitis further highlight the risks associated with Roivant’s current and future product offerings.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares